VX-634
/ Vertex
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
March 12, 2024
A Phase 1, First-in-human Study of VX-634
(clinicaltrials.gov)
- P1 | N=127 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Completed | Trial completion date: Jun 2024 ➔ Nov 2023
Trial completion • Trial completion date • Alpha-1 Antitrypsin Deficiency • Hepatology • Pulmonary Disease • Respiratory Diseases
October 02, 2023
A Phase 1, First-in-human Study of VX-634
(clinicaltrials.gov)
- P1 | N=114 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Trial completion date: Aug 2023 ➔ Jun 2024
Trial completion date • Alpha-1 Antitrypsin Deficiency • Hepatology • Pulmonary Disease • Respiratory Diseases
June 05, 2023
A Phase 1, First-in-human Study of VX-634
(clinicaltrials.gov)
- P1 | N=114 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Trial completion date: Apr 2023 ➔ Aug 2023 | Trial primary completion date: Apr 2023 ➔ Jul 2023
Trial completion date • Trial primary completion date • Alpha-1 Antitrypsin Deficiency • Hepatology • Pulmonary Disease • Respiratory Diseases
November 15, 2022
A Phase 1, First-in-human Study of VX-634
(clinicaltrials.gov)
- P1 | N=114 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting
Enrollment open • Alpha-1 Antitrypsin Deficiency • Hepatology • Pulmonary Disease • Respiratory Diseases
October 13, 2022
A Phase 1, First-in-human Study of VX-634
(clinicaltrials.gov)
- P1 | N=114 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated
New P1 trial • Alpha-1 Antitrypsin Deficiency • Hepatology • Pulmonary Disease • Respiratory Diseases
1 to 5
Of
5
Go to page
1